[go: up one dir, main page]

WO2018154384A1 - Procédé d'assemblage de séquences de poly(acide nucléique) en utilisant des liaisons phosphorothioates à l'intérieur d'oligomères lieurs - Google Patents

Procédé d'assemblage de séquences de poly(acide nucléique) en utilisant des liaisons phosphorothioates à l'intérieur d'oligomères lieurs Download PDF

Info

Publication number
WO2018154384A1
WO2018154384A1 PCT/IB2018/000214 IB2018000214W WO2018154384A1 WO 2018154384 A1 WO2018154384 A1 WO 2018154384A1 IB 2018000214 W IB2018000214 W IB 2018000214W WO 2018154384 A1 WO2018154384 A1 WO 2018154384A1
Authority
WO
WIPO (PCT)
Prior art keywords
linker
dna
assembly
exonuclease
fusions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IB2018/000214
Other languages
English (en)
Inventor
Stephen MCCOLM
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ingenza Ltd
Original Assignee
Ingenza Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ingenza Ltd filed Critical Ingenza Ltd
Priority to EP18714073.6A priority Critical patent/EP3585893B1/fr
Publication of WO2018154384A1 publication Critical patent/WO2018154384A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1093—General methods of preparing gene libraries, not provided for in other subgroups
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/102—Mutagenizing nucleic acids
    • C12N15/1031—Mutagenizing nucleic acids mutagenesis by gene assembly, e.g. assembly by oligonucleotide extension PCR
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/64—General methods for preparing the vector, for introducing it into the cell or for selecting the vector-containing host
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/66—General methods for inserting a gene into a vector to form a recombinant vector using cleavage and ligation; Use of non-functional linkers or adaptors, e.g. linkers containing the sequence for a restriction endonuclease

Definitions

  • the present invention is generally related to the field of synthetic biology. More particularly, the present invention relates to a method of combinatorial polynucleic acid assembly that introduces phosphorothioate bonds into the linker oligos during the assembly procedure in order to use exonucleases to isolate the DNA of interest, thereby eliminating any cumbersome purification steps, such as gel electrophoresis and significantly increasing the overall selectivity and efficiency of the method.
  • the present invention improves on the polynucleic acid assembly method described in U.S. Patent No. 8,999,679 (also referred to herein as inABLE ® assembly or inABLE ® technology) which is incorporated by reference.
  • inABLE ® assembly generally takes DNA truncated parts (TPs), such as genes, from a vector using type lis restriction enzymes, and ligates small DNA "linkers" to the ends of the truncated parts forming part-linker fusions, as shown in FIG. 1.
  • TPs DNA truncated parts
  • the part-oligo annealed "PO A" linker at the end of one part-linker fusion is complementary to the linker-oligo annealed "LOA" linker at the end of a second part-linker fusion.
  • the part-linker fusions can self-assemble with high efficiency into a single piece of DNA in a predetermined order as shown in FIG. 3.
  • the present invention introduces a phosphorothioate bond by replacing a non- bridging oxygen within the phosphate backbone of the nucleic acid sequence with a sulfur (S) atom.
  • S sulfur
  • Introduction of this sulfur atom results in an internucleotide linkage that is resistant to nuclease cleavage. Consequently, by adding such modified S linkers to form nuclease resistant ends of part- linker joined DNA fragments/fusions, the present invention allows the use of exonucleases to degrade parts that do not have linkers ligated to their ends to isolate only the part-linker DNA of interest and avoiding the need for purification by gel electrophoresis.
  • BioBricks (Shetty, R.P., D. Endy, and T.F. Knight, Jr., Engineering BioBrick vectors from BioBrick parts. J Biol Eng, 2008. 2: p. 5) was the first DNA assembly technique to gain traction amongst the scientific community. BioBricks are standardized fragments of DNA which can be joined together in a Lego ® -like fashion. The BioBrick approach allows for the combination of up to three BioBricks with the resulting construct becoming a new BioBrick, thus allowing subsequent rounds of DNA assembly. Both the assembly method and parts are standardized in the sense that the enzymes used are constant and therefore the 5' and 3' terminal sequences are constant.
  • a high-fidelity DNA polymerase fills in any gaps before the nicks in the final construct are sealed by a DNA ligase.
  • the advantages of this technique over BioBricks is the increased number of parts which can be combined, the fact it is largely sequence independent because no specific restriction sites are required to be omitted from part sequences, and that it results in an assembly that does not have to include additional unnecessary nucleotides as a consequence of the method itself.
  • the Gibson method has several disadvantages, including the fact that DNA fragments must be prepared de novo for each assembly, the parts must be at least 250 base pairs, repeated sequences are not tolerated, and the use of a DNA polymerase may impact reliability.
  • PCR polymerase chain reaction
  • PCR polymerase chain reaction
  • Cycles of digestion and ligation are used to reduce re-ligation of original fragments and thereby enrich the product of interest in the mixture.
  • this technique is less sequence independent as it requires the parts to be void of Bsal recognition sites.
  • the Golden Gate method is limited because it results in overhangs of only four nucleotides in length. With a desire to increase selectivity by having at least two nucleotide differences between each set of overhangs, in complex assemblies it may not be possible to find specific overhangs to ensure the efficient assembly of a given fragment using the Golden Gate method.
  • gel electrophoresis is the standard method to purify desired DNA from a mixture.
  • This approach utilizes an electric field to migrate DNA through a gel containing small pores.
  • the fragments of DNA travel through the gel at a speed inversely proportionate to their length. Therefore, smaller fragments travel further on the gel and DNA of the desired size can be identified through comparison with a co-electrophoresed set of DNA fragments of a known size.
  • the desired DNA is subsequently retrieved from the gel through manual excision of the gel fragment and extraction of DNA from the gel matrix using commercially available kits (i.e., QIAquick gel extraction - QIAGEN Corp.). This process results in low throughput and creates a bottleneck in the DNA assembly process.
  • the DNA of interest contains 5' and 3' linkers which constitute an increase in size of ⁇ 50 base pair, over a DNA part which lacks either the 5' and/or or the 3' linker.
  • the part itself can often be > 1000 base pairs in length so this change in size may be only ⁇ 5% and thereby indistinguishable by gel electrophoresis.
  • DNA lacking one (or both) of the linkers can readily be co-extracted and carried through into the assembly stage where its presence is detrimental to the assembly process.
  • inABLE ® assembly combines the advantages of the Gibson assembly (long, single-stranded homologous overhangs) and the Golden Gate assembly (no DNA polymerase needed, a tolerance of repeated sequences, and no limit on DNA length).
  • the technique described in the '679 patent relies on initial cloning of a 5' truncated version of the DNA fragment (referred to as a truncated part) of interest flanked by type lis restriction sites (typically Sapl or Earl).
  • Cycles of digestion and ligation are utilized to initially cleave the truncated part from its cloning vector, prior to annealing linkers to the 5' and 3' of the truncated part (referred to as creation of a part-linker fusion).
  • the ligation of these linkers generates 16 nucleotide single stranded DNA overhangs at each end of the part-linker fusion which provide extensive complementarity between the parts which are to be assembled.
  • multiple part-linker fusions are mixed and assembled in an order specified through the unique complementarity of individual pairs of 16 nucleotide overhangs.
  • Annealing linkers with 16 nucleotide single stranded extensions increases the complementarity between parts (as opposed to short 4 nucleotide single stranded overhangs created by traditional digestion and ligation techniques).
  • the increased length of these extensions greatly increases the selectivity of the process, permitting multiple fragments of DNA to be assembled more efficiently using the inABLE ® assembly, whereas traditional cloning typically allows the efficient ligation of only 2-3 fragments at most.
  • Biotinylated oligos (referred to as purification oligos) complementary to the 16- nucleotide single stranded overhangs of inABLE ® parts can be ordered. However, it is not feasible to confirm whether both 5' and 3' linkers have been attached to a part. For instance, presence of only one linker would still result in the DNA part-linker binding to the streptavidin. In order to purify the desired DNA fragment, the 3' linker must first be ligated, this fragment of DNA purified, and the residual purification oligo removed before the process is repeated for the 5' linker.
  • a major setback with the technology described in the '679 patent is the requirement to purify part-linker fusions through methods such as gel electrophoresis or biotinylated primers and streptavidin beads. Both of these purification approaches have limitations and present a bottleneck in the current workflow.
  • the running of agarose gels and excision of the DNA of interest is a cumbersome, low throughput approach with the added disadvantage that the DNA extracted from the gel is likely a combination of the desired part-linker fusion and fragments that lack one or both linkers, which, along with the residual vector DNA, greatly reduce the efficiency of the DNA assembly stage.
  • the '679 patent describes utilization of biotinylated primers and streptavidin beads as a potential solution to these concerns.
  • the present invention combines the use of phosphorothioate bonds coupled to exonuclease treatment as means to purify DNA within a DNA assembly workflow.
  • Exonucl eases are enzymes which degrade DNA in a stepwise manner from the end of the polynucleotide chain in either a 5' ⁇ 3' or 3' ⁇ 5' direction.
  • Phosphorothioate bonds are generated through replacing a non-bridging oxygen within the phosphate backbone with a sulfur atom.
  • the introduction of the sulfur atom renders the internucleotide linkage resistant to endo- and exonuclease cleavage. This property can be used to protect DNA of interest from exonuclease attack.
  • biotin/streptavidin purification (a separation with potential for contamination by non-specifically bound DNA or a part with a linker attached at only one end).
  • the process does not involve additional steps during ligation of linkers to parts and replaces the gel electrophoresis stage with the addition of an exonuclease and incubation for 30 minutes or less.
  • This enzyme addition and incubation has the potential for extremely high throughput and automation, unlike gel electrophoresis.
  • the present invention addresses the drawbacks of the prior assembly methods by providing a highly selective, efficient and high throughput DNA assembly approach that is easily automated through the use of a liquid handling robot and isolates only the DNA of interest, while degrading the remaining DNA in the reactions. Specifically, the present invention addresses the need for a purification method which matches the specificity and high throughput nature of biotin/streptavidin while reducing the number of steps and overcoming the
  • the present invention describes an improved DNA assembly method having high throughput which can be readily automated to prepare complex polynucleic acid sequences with increased efficiency.
  • the method of assembly disclosed herein describes a novel DNA purification technique that utilizes phosphorothioate linkers and exonucleases to isolate the DNA of interest.
  • a method for assembling polynucleic acids providing at least two DNA truncated parts.
  • a DNA modified linker is ligated to both ends of each DNA truncated part to form at least two part-linker fusions.
  • the DNA modified linker has an internucleotide modification that is resistant to nuclease cleavage.
  • the part-linker fusions are isolated using an exonuclease and the part-linker fusions are joined to form a polynucleic acid sequence.
  • the present invention introduces between 1 and 3
  • POl part-oligo long
  • LOl linker oligo long
  • POs part-oligo short
  • LOs linker-oligo short
  • FIG. 1 The POA and LOA are then ligated to a given part, (cleaved from its cloning vector using Sapl or Earl) resulting in a part- linker fusion which is resistant to cleavage by DNA exonucleases.
  • the cloning vector which originally carried the truncated part, prior to Sapl/Earl digestion as well as any aberrant part-linker fusions are not protected from digestion.
  • This method can be utilized to purify part-linker fusions from contaminating DNA through treatment with an exonuclease.
  • FIG. 1 is a schematic of the generation of a part-linker fusion.
  • FIG. 1 depicts cleavage of truncated part from vector using type lis restriction enzyme (typically Sapl or Earl), followed by ligation of POA and LOA linkers to generate a part-linker fusion.
  • type lis restriction enzyme typically Sapl or Earl
  • FIG. 2 is a detailed schematic of a complete part-linker fusion of the present invention.
  • FIG. 3 is a schematic of DNA assembly part-linker fusions using complementary overhangs between part-linker fusions.
  • FIG. 4 compares the effect of coupled phosphorothioate bonds and Exonuclease III (Exo III) treatment on assembly efficiency for more complex assemblies.
  • Five DNA fragments were assembled, four of which confer resistance to an antibiotic and one an E. coli origin of replication. This allows for selection of cells containing the expected assembly on media supplemented with four antibiotics. The assembly efficiency is calculated by counting the colonies.
  • FIG. 5 is a part-linker fusion reaction analyzed via agarose gel following treatment with various exonucleases.
  • Lane 1 highlights treatment with Exonuclease III (Exo III) which removes the contaminating DNA (higher molecular weight band seen in lanes 2, 4 and 5) while not digesting the phosphorothioate protected part-linker fusion (lower band).
  • Exonucleases explored either did not remove the contaminating DNA (lanes 2, 4 and 5) or digested all DNA present (lane 3).
  • FIG. 6 reports the effect of exonuclease treatment on the assembly efficiency of two fragments of DNA that contain no phosphorothioate bonds. Each fragment conferred resistance to a different antibiotic, allowing for selection of cells harboring the expected assembly on media supplemented with both antibiotics. Counting the number of colonies allows for the assembly efficiency to be calculated.
  • the standard inABLE procedure yielded ⁇ 1400 colonies carrying the expected assembly.
  • treatment with Exo III was used followed by purification via agarose gel this number dropped to -450 colonies, a decrease in transformation efficiency of 68 %. The efficiency further decreases when the exonuclease treatment is followed by a PCR clean up and no purification (-93% decrease).
  • FIG. 7 compares the effect of phosphorothioate bonds on assembly efficiency. Five DNA fragments assembled, four of which confer resistance to an antibiotic and one an E. coli origin of replication. This allows for selection of cells containing the expected assembly on media supplemented with four antibiotics. Through the counting of colonies, the assembly efficiency is calculated.
  • FIG. 8 shows the effect of phosphorothioate bond protected linkers and exonuclease III treatment on assembly accuracy.
  • U.S. Patent No. 8,999,679 discloses assembly of DNA fragments for the construction of complex genetic pathways by cleaving DNA truncated parts, such as genes, regulators, markers, reporters, etc. from a vector using type lis restriction enzymes and ligating small DNA "linkers" to ends of the truncated parts forming part-linker fusions.
  • the '679 patent details the assembly of DNA parts through the use of linkers in a one pot reaction.
  • FIG. 1 depicts the part-linker fusion reaction of the '679 patent, in which the linkers are annealed and then ligated to the truncated part through cycles of digestion and ligation.
  • a reaction mixture is prepared with Earl and the truncated part (TP) on its carrier plasmid.
  • the plasmid releases the TP but the cut plasmid remains in the mixture.
  • POA and LOA are then added with DNA ligase.
  • two things can occur: 1) either the TP rejoins with the plasmid (as shown in 4) or it joins to the POA and LOA (as shown in 5). If the TP rejoins the plasmid, then it is recut by the Earl enzyme still present - because the Earl recognition site is again nearby. If the TP joins to the POA and LOA, then it remains ligated as the Earl cannot cut since its recognition site is no longer nearby. After multiple such cycles the part-link fusion accumulates and little if any TP-plasmid remains. The part-linker fusion still must be purified from the Earl-cut plasmid and any aberrant ligation products.
  • FIG. 2 illustrates the assembly of a complete part-linker of the present invention.
  • a TP of double stranded synthetic DNA is provided.
  • the TP is designed to lack a number of nucleotides at the 5 'end that will ultimately form the POA and LOA sequence.
  • POA refers to two oligonucleotides ("oligos") of DNA, one longer (POl) than the other (POs) but with complementarity (to cause nucleotide pairing) between the short oligo and a region off-center within the long oligo.
  • the annealed POA is joined to the truncated part in the "Ligation/Earl digestion" cyclic reaction shown in FIG. 1.
  • the POA joins to the "upstream” end of the TP.
  • upstream direct mRNA synthesis from coding sequences "downstream”. Therefore "upstream” sequences generally precede the mRNA start and “downstream” sequences follow the mRNA end. In common usage the process is depicted as being left to right (as here) with upstream at the left and downstream to the right.
  • LOA is analogous to the POA, and refers to two oligos of DNA, one longer (LOl) than the other (LOs) but with complementarity (to cause nucleotide pairing) between the short oligo and a region off-center within the long oligo.
  • the annealed LOA is also joined to the truncated part in the "Ligation/Earl digestion" cyclic reaction as shown in FIG. 1, but joins to the "downstream" end of the TP.
  • the part-linker fusion refers to the three fragments (POA-TP- LOA) which are then joined in the cyclic reaction shown in FIG. 3. Using the usual left to right convention (i.e.
  • FIG. 3 depicts the assembly of individual part-linker fusions which can anneal and assemble using the 16-nucleotide single stranded extensions.
  • the part-linker fusions can self-assemble selectively into one piece of DNA in a predetermined order, as shown in FIG. 3.
  • the POA and LOA linkers contain -16 nucleotide single stranded overhangs which provide complementarity between the fragments of DNA. Overhangs are then utilized to assemble the fragments of DNA in a predefined order with efficiency not achievable with standard molecular cloning.
  • part-linker assembly is achieved by joining multiple part-linker fusions.
  • various part-linker fusions POA-TP-LOA
  • the part-linker fusions are then incubated together. During incubation, the part-linker fusions will anneal very selectively due to long (16bp) single stranded complementary overlaps that are designed between a specific POA and LOA. As a result, large assemblies are formed.
  • An internucleotide modification resistant to nuclease cleavage is made in the POl and LOl as shown in FIGS. 2 and 3. In one embodiment the internucleotide modification is a phosphorothioate bond.
  • the presence of these phosphorothioate bonds are utilized to purify the part-linker DNA using an exonuclease treatment that yields additional benefits not known in the art.
  • the use of this technique highlights the requirement to purify the DNA fragments after ligation of the linkers to a given part, which is the key bottleneck in the technique.
  • the present invention provides a DNA purification method that results in greater process efficiency through higher throughput and specificity in reduced time, while permitting automation of the entire process by eliminating the need for gel electrophoresis.
  • each part requires a part-linker fusion step.
  • Automation of the part-linker fusion reaction can be achieved through the use of a liquid handling robot.
  • each part-linker fusion must be purified via gel electrophoresis, which is a cumbersome rate limiting step that results in significant residual quantities of contaminating DNA fragments (non-ligated or partially ligated part and linker).
  • the requirement to run a gel to purify the part-linker fusion limits the compatibility of the inABLE ® assembly with automation and the purity of the desired part-linker fusion.
  • Exonucleases are enzymes which degrade DNA in a stepwise manner from the end of the polynucleotide chain. Exonucleases are enzymes which cleave nucleotides one at a time from the end of a polynucleotide chain in either a 5' ⁇ 3' or 3' ⁇ 5' direction. The introduction of a phosphorothioate bond renders the internucleotide linkage resistant to exonuclease cleavage. This property can be used to protect DNA of interest from exonuclease attack.
  • the present invention combines the use of phosphorothioate bonds and exonucleases as a means to purify DNA within a DNA assembly workflow.
  • the present invention forms a phosphorothioate bond by replacing a non-bridging oxygen within the phosphate backbone with a sulfur atom during the part-linker fusion step as shown in FIGS. 2 and 3.
  • the present invention introduces between at least 1 and 3 phosphorothioate linkages at the 3 ' end of the POl and LOl oligonucleotide (annealed with POs and LOs to generate POA and LOA respectively), as shown in FIG.
  • part-linker fusions which are resistant to cleavage by exonucleases.
  • phosphorothioate containing linkers are known in the art and may be purchased with the S -modification at low cost from major suppliers such as Sigma Aldrich or Integrated DNA Technologies.
  • the vector which carried the truncated part prior to Sapl/Earl digestion and any aberrant part-linkers are not protected.
  • the present invention can be utilized to purify part-linker fusions from all contaminating DNA which could be present following other purification methods, through treatment with an exonuclease.
  • the present invention details the steps of the inABLE ® assembly method - ligation of linkers to truncated part through cycles of digestion and ligation.
  • the present invention eliminates the need for the "part purification (agarose gel)" step. Instead, the present invention allows for part purification with the use of exonucleases. Since the exonuclease is unable to cleave
  • exonuclease while the remaining DNA in the reaction, including the vector backbone and aberrant part-linkers (i.e. missing either POA and/or LOA) are digested by the exonuclease.
  • Exonucleases are known in the art and are available for purchase by any provider such as NEB or Thermo. It is important the exonuclease used with the present invention is phosphorothioate sensitive, such as Exo III. While the present invention uses exonucleases active in the 3' to 5' direction, exonucleases which are active in the 5' to 3' direction may similarly be utilized in circumstances where 5' single stranded overhangs are utilized in place of 3' single stranded overhangs
  • the present invention provides a technique amenable to automation and results in an increase in the overall assembly reaction efficiency and assembly accuracy. For instance, when the "part-linker fusion" band is excised from a gel it is likely that within the DNA extracted there will be a percentage of aberrant part-linker fusions (i.e. TP+POA bound but not LOA or vice versa). The introduction of the exonuclease treatment will remove these fragments, thereby resulting in much greater overall DNA assembly efficiency.
  • the DNA purification approach of the present invention may not be suitable for other DNA assembly techniques disclosed in the prior art, such as the Golden Gate and Gibson assemblies, since they both rely on the use of either PCR products or cloned DNA fragments, in which phosphorothioate bonds cannot be introduced.
  • it is particularly suitable for DNA assembly using the inABLE ® assembly techniques utilized by Ingenza (and described in the '679 patent, which is incorporated by reference) since the linkers are synthetic fragments of DNA which can be modified during synthesis.
  • the present invention provides at least the following advantages not previously available with current DNA assembly methods.
  • each part requiring assembly must go through a part-linker fusion.
  • Automation of part-linker fusion reaction preparation is feasible through the use of a liquid handling robot.
  • each part-linker fusion requires purification via gel electrophoresis, limiting the potential for automation. Attempts to omit the gel extraction stage result in a significant decrease in assembly efficiency likely due to the presence of contaminating fragments or vector being carried through to the assembly reaction.
  • the part-linker fusion (POA::TP: :LOA) is protected from the exonuclease, while the vector backbone is degraded.
  • the present inABLE assembly technique utilizes gel electrophoresis to separate the part-linker fusions from the vector backbone.
  • gel electrophoresis to separate the part-linker fusions from the vector backbone.
  • part-linker fusions i.e., missing either POA and/or LOA.
  • Aberrant part/linkers are incomplete or incorrect part/linkers. These fragments have an inhibitory effect on the assembly reaction and despite this are currently carried through, diminishing overall assembly efficiency.
  • the present invention does not rely on separation of the required DNA from contaminants but instead complete removal of the contaminating DNA.
  • the present invention does not require the addition of ligase during the assembly reaction. Attempts to include ligase in the assembly reaction results in a modest increase in assembly efficiency, but a pronounced increase in the number of incorrect assemblies.
  • E. coli Exonuclease III has been shown to act at nicks in a 3' ⁇ 5' manner. The introduction of phosphorothioate bonds at the 3' end of the POl and LOl confers resistance at nicks present in the assembled vector to this exonuclease in vivo.
  • NEB 10 ⁇ cells Chemically competent NEB 10 ⁇ cells (NEB) were transformed with 3 ⁇ of the assembly reaction following the manufacturer's guidelines. Dilutions of the transformation reaction were plated onto LB agar plates containing the appropriate antibiotics and the plates incubated overnight at 37 °C.
  • Exonuclease I and III both from E. coli
  • Exonuclease T and Bal-34 are reported to have potentially compatible characteristics with the present invention and were explored in an initial study. From this selection of 3' - 5' exonucleases, only Exonuclease III was found to remove contaminating DNA from the reaction while the phosphorothioate protected part-linker fusion was resistant to degradation.
  • a part-linker fusion reaction was analyzed via agarose gel following exonuclease treatment.
  • Lane 1 highlights treatment with Exonuclease III removing the contaminating DNA (higher molecular weight band seen in lanes 2, 4 and 5) while not digesting the phosphorothioate protected part-linker fusion (lower band).
  • the other exonucleases tested either did not remove the contaminating DNA (lanes 2, 4 and 5) or digested all DNA present (lane 3).
  • Exonuclease III treatment without the use of phosphorothioate bonds was explored to determine if an exonuclease treatment alone is sufficient.
  • a review of the characteristics of Exonuclease III suggests that it should be suitable to remove contaminating DNA from the reaction without digesting the part-linker fusion (removing the requirement for phosphorothioate bonds). This is due to its preferred substrates being blunt or recessed 3' termini with the 3' extensions over 4 bases or longer essentially being resistant to cleavage.
  • Example 1 As described in Example 1 a two-part assembly was performed which allowed for assemblies to be verified through antibiotic resistance. Part-linker fusions were treated with Exonuclease III and either purified by agarose gel, PCR purification or not purified following exonuclease treatment. In parallel the inABLE procedure was performed as standard (no exonuclease treatment and including agarose gel-based purification). Assembly reactions and E. coli transformation were performed using the protocol described in Example 1. Dilutions of the transformation reaction were plated onto LB agar plates containing the appropriate antibiotics and the plates incubated overnight at 37 °C.
  • E. coli Exonuclease III has been characterized as being able to initiate degradation at plasmid nicks in a 3' ⁇ 5' manner.
  • the introduction of phosphorothioate bonds at the 3' end of the POl and LOl confers resistance at nicks present in the assembled vector to this E. coli exonuclease in vivo.

Landscapes

  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Cell Biology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

La présente invention concerne un procédé d'assemblage de poly(acides nucléiques) qui introduit des liaisons phosphorothioates dans des oligomères lieurs durant la procédure d'assemblage afin d'utiliser des exonucléases pour isoler l'ADN d'intérêt, éliminant ainsi toutes les étapes de purification fastidieuses, telles que l'électrophorèse sur gel et qui accroît de manière considérable la sélectivité et l'efficacité globales du procédé. La présente invention introduit une liaison phosphorothioate en remplaçant un oxygène non pontant à l'intérieur du squelette phosphate de la séquence d'acides nucléiques par un atome de soufre (S). L'introduction de cet atome de soufre résulte en une liaison internucléotidique qui est résistante au clivage par nucléase. En conséquence, en ajoutant de tels lieurs (S) modifiés pour former des extrémités résistantes à la nucléase de l'ADN partie-lieur, la présente invention permet l'utilisation des exonucléases pour dégrader des parties qui ne présentent pas de lieurs ligaturés à leurs extrémités pour isoler uniquement l'ADN partie-lieur d'intérêt pour accroître l'efficacité et la sélectivité de l'assemblage et éviter le besoin de purification par électrophorèse sur gel.
PCT/IB2018/000214 2017-02-22 2018-02-21 Procédé d'assemblage de séquences de poly(acide nucléique) en utilisant des liaisons phosphorothioates à l'intérieur d'oligomères lieurs Ceased WO2018154384A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP18714073.6A EP3585893B1 (fr) 2017-02-22 2018-02-21 Procédé d'assemblage de séquences de poly(acide nucléique) en utilisant des liaisons phosphorothioates à l'intérieur d'oligomères lieurs

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762461938P 2017-02-22 2017-02-22
US62/461,938 2017-02-22

Publications (1)

Publication Number Publication Date
WO2018154384A1 true WO2018154384A1 (fr) 2018-08-30

Family

ID=61802233

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2018/000214 Ceased WO2018154384A1 (fr) 2017-02-22 2018-02-21 Procédé d'assemblage de séquences de poly(acide nucléique) en utilisant des liaisons phosphorothioates à l'intérieur d'oligomères lieurs

Country Status (3)

Country Link
US (1) US20180362965A1 (fr)
EP (1) EP3585893B1 (fr)
WO (1) WO2018154384A1 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023096650A1 (fr) * 2021-11-26 2023-06-01 National Health Research Institutes Procédé de terminaison d'un adn double brin par au moins une tige-boucle et kit associé
US12018316B2 (en) 2020-03-03 2024-06-25 Telesis Bio Inc. Methods for assembling nucleic acids
WO2025064396A1 (fr) * 2023-09-18 2025-03-27 Intellia Therapeutics, Inc. Produit d'adn double brin résistant aux nucléases pour administration non virale à une cellule et ses procédés de production

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003027258A2 (fr) * 2001-09-28 2003-04-03 Sigma-Aldrich Co. Procedes de production d'adn recombine comprenant l'utilisation d'un melange dntp contenant des nucleotides modifies
WO2009023676A1 (fr) * 2007-08-12 2009-02-19 Integrated Dna Technologies, Inc. Système de microréseau avec spécificité de séquence améliorée
WO2009103027A2 (fr) * 2008-02-15 2009-08-20 Synthetic Genomics, Inc. Procédés de jonction in vitro et d’assemblage combinatoire de molécules d’acides nucléiques
WO2010070295A1 (fr) * 2008-12-18 2010-06-24 Iti Scotland Limited Procédé d'assemblage de séquences d'acide polynucléique
EP2395087A1 (fr) * 2010-06-11 2011-12-14 Icon Genetics GmbH Système et procédé de clonage modulaire
WO2011161413A2 (fr) * 2010-06-23 2011-12-29 Iti Scotland Limited Procédé et dispositif

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003027258A2 (fr) * 2001-09-28 2003-04-03 Sigma-Aldrich Co. Procedes de production d'adn recombine comprenant l'utilisation d'un melange dntp contenant des nucleotides modifies
WO2009023676A1 (fr) * 2007-08-12 2009-02-19 Integrated Dna Technologies, Inc. Système de microréseau avec spécificité de séquence améliorée
WO2009103027A2 (fr) * 2008-02-15 2009-08-20 Synthetic Genomics, Inc. Procédés de jonction in vitro et d’assemblage combinatoire de molécules d’acides nucléiques
WO2010070295A1 (fr) * 2008-12-18 2010-06-24 Iti Scotland Limited Procédé d'assemblage de séquences d'acide polynucléique
US8999679B2 (en) 2008-12-18 2015-04-07 Iti Scotland Limited Method for assembly of polynucleic acid sequences
EP2395087A1 (fr) * 2010-06-11 2011-12-14 Icon Genetics GmbH Système et procédé de clonage modulaire
WO2011161413A2 (fr) * 2010-06-23 2011-12-29 Iti Scotland Limited Procédé et dispositif

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
ENGLER, C.; R. KANDZIA; S. MARILLONNET: "A One Pot, One Step, Precision Cloning Method with High Throughput Capability", PLOS ONE, vol. 3, no. 11, 2008, pages e3647, XP002613221, DOI: doi:10.1371/journal.pone.0003647
GIBSON, D.G. ET AL.: "Enzymatic assembly of DNA molecules up to several hundred kilobases", NAT METH, vol. 6, no. 5, 2009, pages 343 - 345, XP055224105, DOI: doi:10.1038/nmeth.1318
LU CHENFENG ET AL: "Comparison of multiple gene assembly methods for metabolic engineering", APPLIED BIOCHEMISTRY AND BIOTECHNOLOGY ; PART A: ENZYME ENGINEERING AND BIOTECHNOLOGY, HUMANA PRESS INC, NEW YORK, vol. 137, 1 April 2007 (2007-04-01), pages 703 - 710, XP002569290, ISSN: 0273-2289 *
MARKO STORCH ET AL: "BASIC: A New Biopart Assembly Standard for Idempotent Cloning Provides Accurate, Single-Tier DNA Assembly for Synthetic Biology", ACS SYNTHETIC BIOLOGY, vol. 4, no. 7, 17 July 2015 (2015-07-17), Washington, DC,USA, pages 781 - 787, XP055343133, ISSN: 2161-5063, DOI: 10.1021/sb500356d *
RESHMA P SHETTY ET AL: "Engineering BioBrick vectors from BioBrick parts", JOURNAL OF BIOLOGICAL ENGINEERING, vol. 2, no. 1, 1 January 2008 (2008-01-01), pages 5, XP055065521, ISSN: 1754-1611, DOI: 10.1186/1754-1611-2-5 *
SHETTY, R.P.; D. ENDY; T.F. KNIGHT, JR.: "Engineering BioBrick vectors from BioBrick parts", J BIOL ENG, vol. 2, 2008, pages 5, XP055065521, DOI: doi:10.1186/1754-1611-2-5

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12018316B2 (en) 2020-03-03 2024-06-25 Telesis Bio Inc. Methods for assembling nucleic acids
WO2023096650A1 (fr) * 2021-11-26 2023-06-01 National Health Research Institutes Procédé de terminaison d'un adn double brin par au moins une tige-boucle et kit associé
WO2025064396A1 (fr) * 2023-09-18 2025-03-27 Intellia Therapeutics, Inc. Produit d'adn double brin résistant aux nucléases pour administration non virale à une cellule et ses procédés de production

Also Published As

Publication number Publication date
EP3585893A1 (fr) 2020-01-01
EP3585893B1 (fr) 2021-10-13
US20180362965A1 (en) 2018-12-20

Similar Documents

Publication Publication Date Title
US11408020B2 (en) Methods for in vitro joining and combinatorial assembly of nucleic acid molecules
KR102098915B1 (ko) 키메라 게놈 조작 분자 및 방법
Kim et al. Genome‐wide analysis of Agrobacterium T‐DNA integration sites in the Arabidopsis genome generated under non‐selective conditions
CA2907198C (fr) Utilisation de nucleases foki a guidage arn (rfn) pour augmenter la specificite pour la modification d'un genome a guidage arn
CN109844113B (zh) 序列和长度确定的dna单链分子的可扩展性的生物技术生产
EP2748318B1 (fr) Compositions et procédés pour un assemblage haute-fidélité d'acides nucléiques
EP2961866B1 (fr) Procédés de production de bibliothèques pour une évolution dirigée
CN114410625A (zh) 通过Cas9-crRNA复合物的RNA指导的DNA裂解
CN102007212A (zh) 同源重组方法和克隆方法以及试剂盒
US20160340670A1 (en) Novel oligo-linker-mediated dna assembly method and applications thereof
WO2017223127A1 (fr) Modulation à base de fréquence de diverses espèces dans une bibliothèque d'acides nucléiques
CN104232627A (zh) 2b-RAD混合建库技术
EP3872171A1 (fr) Détection d'arn et édition dépendant de la transcription à l'aide d'arncr transactivateurs reprogrammés
EP3585893B1 (fr) Procédé d'assemblage de séquences de poly(acide nucléique) en utilisant des liaisons phosphorothioates à l'intérieur d'oligomères lieurs
US10837012B2 (en) Compositions and methods for polynucleotide assembly
Meers et al. Transposon-encoded nucleases use guide RNAs to selfishly bias their inheritance
WO2020172199A1 (fr) Construction de banques de brins guides et procédés d'utilisation associés
US20240301445A1 (en) Crispr-associated transposon systems and methods of using same
CN112996927A (zh) Gramc：顺式调节模块的基因组规模报道子测定方法
JP2024509047A (ja) Ｃｒｉｓｐｒ関連トランスポゾンシステム及びその使用方法
CN114286861A (zh) 捕获和分析靶基因组区域
WO2023004422A2 (fr) Systèmes de transposon associés à crispr et leurs méthodes d'utilisation
US20240043834A1 (en) Linked dna production method and vector combination for use therein
CN114507903A (zh) 质粒测序方法
US20250257364A1 (en) Rna-guided dna transposition

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18714073

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2018714073

Country of ref document: EP

Effective date: 20190923